XTRA:BAYNPharmaceuticals
Bayer (XTRA:BAYN) Valuation Check As AI Antibody Collaboration With Cradle Gains Attention
Bayer (XTRA:BAYN) has agreed to a three-year collaboration with Cradle to bring generative AI tools into its therapeutic antibody research, aiming to speed up molecule design, refine antibody properties, and streamline clinical development workflows.
See our latest analysis for Bayer.
The collaboration with Cradle comes at a time when Bayer’s share price has a 30 day share price return of 9.98% and a 90 day share price return of 35.99%, while the 1 year total shareholder return of 95.94%...